Pharmaids Pharmaceuticals Limited

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, MEDPLUS.NS has a market cap of 100.8B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while MEDPLUS.NS trades at ₹827.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas MEDPLUS.NS's P/E ratio is 48.77. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to MEDPLUS.NS's ROE of +0.12%. Regarding short-term risk, PHARMAID.BO is more volatile compared to MEDPLUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check MEDPLUS.NS's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, MEDPLUS.BO has a market cap of 100.5B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while MEDPLUS.BO trades at ₹831.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas MEDPLUS.BO's P/E ratio is 48.54. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to MEDPLUS.BO's ROE of +0.12%. Regarding short-term risk, PHARMAID.BO is more volatile compared to MEDPLUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check MEDPLUS.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, GUJTHEM.BO has a market cap of 24.8B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while GUJTHEM.BO trades at ₹245.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas GUJTHEM.BO's P/E ratio is 51.69. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to GUJTHEM.BO's ROE of +0.19%. Regarding short-term risk, PHARMAID.BO is more volatile compared to GUJTHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check GUJTHEM.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, KPL.BO has a market cap of 13.6B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while KPL.BO trades at ₹1,425.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas KPL.BO's P/E ratio is 23.96. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to KPL.BO's ROE of +0.21%. Regarding short-term risk, PHARMAID.BO is more volatile compared to KPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check KPL.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SHUKRAPHAR.BO has a market cap of 13.3B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SHUKRAPHAR.BO trades at ₹31.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SHUKRAPHAR.BO's P/E ratio is -151.70. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SHUKRAPHAR.BO's ROE of +0.47%. Regarding short-term risk, PHARMAID.BO is more volatile compared to SHUKRAPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check SHUKRAPHAR.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, FREDUN.BO has a market cap of 9B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while FREDUN.BO trades at ₹1,728.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas FREDUN.BO's P/E ratio is 23.90. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to FREDUN.BO's ROE of +0.23%. Regarding short-term risk, PHARMAID.BO is more volatile compared to FREDUN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check FREDUN.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SASTASUNDR.BO has a market cap of 8.3B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SASTASUNDR.BO trades at ₹267.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SASTASUNDR.BO's P/E ratio is 31.98. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SASTASUNDR.BO's ROE of +0.03%. Regarding short-term risk, PHARMAID.BO is more volatile compared to SASTASUNDR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check SASTASUNDR.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SASTASUNDR.NS has a market cap of 8.2B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SASTASUNDR.NS trades at ₹270.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SASTASUNDR.NS's P/E ratio is 31.37. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SASTASUNDR.NS's ROE of +0.03%. Regarding short-term risk, PHARMAID.BO is more volatile compared to SASTASUNDR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check SASTASUNDR.NS's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, ANUHPHR.BO has a market cap of 6.7B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while ANUHPHR.BO trades at ₹73.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas ANUHPHR.BO's P/E ratio is 16.10. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to ANUHPHR.BO's ROE of +0.13%. Regarding short-term risk, PHARMAID.BO is more volatile compared to ANUHPHR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check ANUHPHR.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, BPLPHARMA.BO has a market cap of 6.2B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while BPLPHARMA.BO trades at ₹1,045.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas BPLPHARMA.BO's P/E ratio is -21.05. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to BPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, PHARMAID.BO is less volatile compared to BPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check BPLPHARMA.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while ALBERTDA.BO trades at ₹1,084.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to ALBERTDA.BO's ROE of +0.02%. Regarding short-term risk, PHARMAID.BO is more volatile compared to ALBERTDA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check ALBERTDA.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SUDARSHAN.BO has a market cap of 5.8B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SUDARSHAN.BO trades at ₹25.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SUDARSHAN.BO's P/E ratio is 28.86. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SUDARSHAN.BO's ROE of +0.15%. Regarding short-term risk, PHARMAID.BO is more volatile compared to SUDARSHAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check SUDARSHAN.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SGRL.BO has a market cap of 5.4B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SGRL.BO trades at ₹449.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SGRL.BO's P/E ratio is 29.79. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SGRL.BO's ROE of +0.13%. Regarding short-term risk, PHARMAID.BO is more volatile compared to SGRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check SGRL.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, PRAVEG.BO has a market cap of 4.8B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while PRAVEG.BO trades at ₹194.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas PRAVEG.BO's P/E ratio is -126.28. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to PRAVEG.BO's ROE of -0.01%. Regarding short-term risk, PHARMAID.BO is more volatile compared to PRAVEG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check PRAVEG.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, VIKRAMTH.BO has a market cap of 4.3B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while VIKRAMTH.BO trades at ₹143.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas VIKRAMTH.BO's P/E ratio is 12.53. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to VIKRAMTH.BO's ROE of +0.28%. Regarding short-term risk, PHARMAID.BO is more volatile compared to VIKRAMTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check VIKRAMTH.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, JENBURPH.BO has a market cap of 4.2B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while JENBURPH.BO trades at ₹1,007.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas JENBURPH.BO's P/E ratio is 13.00. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to JENBURPH.BO's ROE of +0.19%. Regarding short-term risk, PHARMAID.BO is more volatile compared to JENBURPH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check JENBURPH.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, TLL.BO has a market cap of 3.2B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while TLL.BO trades at ₹266.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas TLL.BO's P/E ratio is 21.55. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to TLL.BO's ROE of +0.24%. Regarding short-term risk, PHARMAID.BO is less volatile compared to TLL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check TLL.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, INFINIUM.NS has a market cap of 3B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while INFINIUM.NS trades at ₹202.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas INFINIUM.NS's P/E ratio is 31.97. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to INFINIUM.NS's ROE of N/A. Regarding short-term risk, PHARMAID.BO is more volatile compared to INFINIUM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check INFINIUM.NS's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, ZENOTECH.BO has a market cap of 2.1B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while ZENOTECH.BO trades at ₹37.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas ZENOTECH.BO's P/E ratio is 62.35. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to ZENOTECH.BO's ROE of +0.03%. Regarding short-term risk, PHARMAID.BO is more volatile compared to ZENOTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check ZENOTECH.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, BDH.BO has a market cap of 2B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while BDH.BO trades at ₹381.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas BDH.BO's P/E ratio is 19.50. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to BDH.BO's ROE of +0.15%. Regarding short-term risk, PHARMAID.BO is more volatile compared to BDH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check BDH.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, TRANSCHEM.BO has a market cap of 2B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while TRANSCHEM.BO trades at ₹154.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas TRANSCHEM.BO's P/E ratio is 67.77. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to TRANSCHEM.BO's ROE of +0.04%. Regarding short-term risk, PHARMAID.BO is more volatile compared to TRANSCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check TRANSCHEM.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, KERALAYUR.BO has a market cap of 1.9B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while KERALAYUR.BO trades at ₹179.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas KERALAYUR.BO's P/E ratio is -8.05. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to KERALAYUR.BO's ROE of -1.45%. Regarding short-term risk, PHARMAID.BO is less volatile compared to KERALAYUR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check KERALAYUR.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, AMBALALSA.BO has a market cap of 1.9B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while AMBALALSA.BO trades at ₹26.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas AMBALALSA.BO's P/E ratio is 17.85. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to AMBALALSA.BO's ROE of +0.08%. Regarding short-term risk, PHARMAID.BO is more volatile compared to AMBALALSA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check AMBALALSA.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SYSCHEM.BO has a market cap of 1.8B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SYSCHEM.BO trades at ₹44.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SYSCHEM.BO's P/E ratio is 27.92. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SYSCHEM.BO's ROE of +0.10%. Regarding short-term risk, PHARMAID.BO is more volatile compared to SYSCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check SYSCHEM.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, OXYGENTAPH.BO has a market cap of 1.8B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while OXYGENTAPH.BO trades at ₹47.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas OXYGENTAPH.BO's P/E ratio is -10.25. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to OXYGENTAPH.BO's ROE of +0.58%. Regarding short-term risk, PHARMAID.BO is more volatile compared to OXYGENTAPH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check OXYGENTAPH.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, GENNEX.BO has a market cap of 1.7B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while GENNEX.BO trades at ₹8.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas GENNEX.BO's P/E ratio is 9.64. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to GENNEX.BO's ROE of +0.09%. Regarding short-term risk, PHARMAID.BO is less volatile compared to GENNEX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check GENNEX.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, QUESTLAB.NS has a market cap of 1.7B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while QUESTLAB.NS trades at ₹102.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas QUESTLAB.NS's P/E ratio is 12.61. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to QUESTLAB.NS's ROE of N/A. Regarding short-term risk, PHARMAID.BO is more volatile compared to QUESTLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check QUESTLAB.NS's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, AUROLAB.BO has a market cap of 1.7B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while AUROLAB.BO trades at ₹271.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas AUROLAB.BO's P/E ratio is 51.06. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to AUROLAB.BO's ROE of +0.07%. Regarding short-term risk, PHARMAID.BO is more volatile compared to AUROLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check AUROLAB.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SANJIVIN.BO has a market cap of 1.6B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SANJIVIN.BO trades at ₹154.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SANJIVIN.BO's P/E ratio is 20.11. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SANJIVIN.BO's ROE of +0.20%. Regarding short-term risk, PHARMAID.BO is less volatile compared to SANJIVIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check SANJIVIN.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, NATCAPSUQ.BO has a market cap of 1.5B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while NATCAPSUQ.BO trades at ₹154.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas NATCAPSUQ.BO's P/E ratio is -7.81. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to NATCAPSUQ.BO's ROE of -0.08%. Regarding short-term risk, PHARMAID.BO is more volatile compared to NATCAPSUQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check NATCAPSUQ.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, PARNAXLAB.BO has a market cap of 1.5B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while PARNAXLAB.BO trades at ₹133.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas PARNAXLAB.BO's P/E ratio is 11.79. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to PARNAXLAB.BO's ROE of +0.15%. Regarding short-term risk, PHARMAID.BO is more volatile compared to PARNAXLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check PARNAXLAB.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, CORALAB.BO has a market cap of 1.3B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while CORALAB.BO trades at ₹383.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas CORALAB.BO's P/E ratio is 9.47. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to CORALAB.BO's ROE of +0.07%. Regarding short-term risk, PHARMAID.BO is more volatile compared to CORALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check CORALAB.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SOTAC.NS has a market cap of 1.2B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SOTAC.NS trades at ₹108.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SOTAC.NS's P/E ratio is 14.11. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SOTAC.NS's ROE of N/A. Regarding short-term risk, PHARMAID.BO is more volatile compared to SOTAC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check SOTAC.NS's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, PANCHSHEEL.BO has a market cap of 1.2B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while PANCHSHEEL.BO trades at ₹102.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas PANCHSHEEL.BO's P/E ratio is 9.87. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to PANCHSHEEL.BO's ROE of +0.09%. Regarding short-term risk, PHARMAID.BO is less volatile compared to PANCHSHEEL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check PANCHSHEEL.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, KIMIABL.BO has a market cap of 1.1B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while KIMIABL.BO trades at ₹25.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas KIMIABL.BO's P/E ratio is N/A. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to KIMIABL.BO's ROE of +0.92%. Regarding short-term risk, PHARMAID.BO is less volatile compared to KIMIABL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check KIMIABL.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SMRUTHIORG.BO has a market cap of 1.1B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SMRUTHIORG.BO trades at ₹101.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SMRUTHIORG.BO's P/E ratio is 24.06. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SMRUTHIORG.BO's ROE of +0.07%. Regarding short-term risk, PHARMAID.BO is more volatile compared to SMRUTHIORG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check SMRUTHIORG.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, TYCHE.BO has a market cap of 1B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while TYCHE.BO trades at ₹109.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas TYCHE.BO's P/E ratio is 15.01. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to TYCHE.BO's ROE of +0.05%. Regarding short-term risk, PHARMAID.BO is less volatile compared to TYCHE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check TYCHE.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, LACTOSE.BO has a market cap of 1B. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while LACTOSE.BO trades at ₹84.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas LACTOSE.BO's P/E ratio is 20.83. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to LACTOSE.BO's ROE of +0.08%. Regarding short-term risk, PHARMAID.BO is more volatile compared to LACTOSE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check LACTOSE.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, MERCURYLAB.BO has a market cap of 840M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while MERCURYLAB.BO trades at ₹721.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas MERCURYLAB.BO's P/E ratio is 17.79. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to MERCURYLAB.BO's ROE of +0.09%. Regarding short-term risk, PHARMAID.BO is more volatile compared to MERCURYLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check MERCURYLAB.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, MAKERSL.BO has a market cap of 797.7M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while MAKERSL.BO trades at ₹156.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas MAKERSL.BO's P/E ratio is 65.31. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to MAKERSL.BO's ROE of +0.01%. Regarding short-term risk, PHARMAID.BO is less volatile compared to MAKERSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check MAKERSL.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, DENISCHEM.BO has a market cap of 784.6M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while DENISCHEM.BO trades at ₹63.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas DENISCHEM.BO's P/E ratio is 9.00. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to DENISCHEM.BO's ROE of +0.10%. Regarding short-term risk, PHARMAID.BO is less volatile compared to DENISCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check DENISCHEM.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, CONCORD.BO has a market cap of 698.8M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while CONCORD.BO trades at ₹70.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas CONCORD.BO's P/E ratio is 159.61. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to CONCORD.BO's ROE of +0.02%. Regarding short-term risk, PHARMAID.BO is more volatile compared to CONCORD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check CONCORD.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SOURCENTRL.BO has a market cap of 698.4M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SOURCENTRL.BO trades at ₹114.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SOURCENTRL.BO's P/E ratio is 25.12. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SOURCENTRL.BO's ROE of +0.12%. Regarding short-term risk, PHARMAID.BO is more volatile compared to SOURCENTRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check SOURCENTRL.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, BACPHAR.BO has a market cap of 685.1M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while BACPHAR.BO trades at ₹50.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas BACPHAR.BO's P/E ratio is 95.46. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to BACPHAR.BO's ROE of +0.04%. Regarding short-term risk, PHARMAID.BO is more volatile compared to BACPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check BACPHAR.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, GODAVARI.BO has a market cap of 647.8M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while GODAVARI.BO trades at ₹92.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas GODAVARI.BO's P/E ratio is -94.53. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to GODAVARI.BO's ROE of +0.08%. Regarding short-term risk, PHARMAID.BO is less volatile compared to GODAVARI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check GODAVARI.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SUNLOC.BO has a market cap of 635.5M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SUNLOC.BO trades at ₹61.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SUNLOC.BO's P/E ratio is 22.21. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SUNLOC.BO's ROE of +0.04%. Regarding short-term risk, PHARMAID.BO is more volatile compared to SUNLOC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check SUNLOC.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, BIBCL.BO has a market cap of 615.3M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while BIBCL.BO trades at ₹15.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas BIBCL.BO's P/E ratio is -4.91. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, PHARMAID.BO is less volatile compared to BIBCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check BIBCL.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, ZENITHDRUG.NS has a market cap of 603.6M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while ZENITHDRUG.NS trades at ₹38.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas ZENITHDRUG.NS's P/E ratio is 8.42. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to ZENITHDRUG.NS's ROE of N/A. Regarding short-term risk, PHARMAID.BO is more volatile compared to ZENITHDRUG.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check ZENITHDRUG.NS's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, PHRMASI.BO has a market cap of 513.4M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while PHRMASI.BO trades at ₹75.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas PHRMASI.BO's P/E ratio is 2.89. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to PHRMASI.BO's ROE of +1.86%. Regarding short-term risk, PHARMAID.BO is more volatile compared to PHRMASI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check PHRMASI.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, VILINBIO.NS has a market cap of 511.3M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while VILINBIO.NS trades at ₹37.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas VILINBIO.NS's P/E ratio is 229.06. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to VILINBIO.NS's ROE of N/A. Regarding short-term risk, PHARMAID.BO is more volatile compared to VILINBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check VILINBIO.NS's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, VEERHEALTH.BO has a market cap of 402.8M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while VEERHEALTH.BO trades at ₹20.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas VEERHEALTH.BO's P/E ratio is 50.35. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to VEERHEALTH.BO's ROE of +0.04%. Regarding short-term risk, PHARMAID.BO is more volatile compared to VEERHEALTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check VEERHEALTH.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, PANJON.BO has a market cap of 381.1M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while PANJON.BO trades at ₹24.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas PANJON.BO's P/E ratio is 88.80. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to PANJON.BO's ROE of +0.05%. Regarding short-term risk, PHARMAID.BO is more volatile compared to PANJON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check PANJON.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, VISTAPH.BO has a market cap of 376.1M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while VISTAPH.BO trades at ₹6.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas VISTAPH.BO's P/E ratio is -4.66. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to VISTAPH.BO's ROE of -0.17%. Regarding short-term risk, PHARMAID.BO is more volatile compared to VISTAPH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check VISTAPH.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, VRL.BO has a market cap of 335.8M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while VRL.BO trades at ₹111.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas VRL.BO's P/E ratio is 8.98. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to VRL.BO's ROE of +0.10%. Regarding short-term risk, PHARMAID.BO is more volatile compared to VRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check VRL.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SHELTER.BO has a market cap of 310.3M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SHELTER.BO trades at ₹29.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SHELTER.BO's P/E ratio is 4.96. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SHELTER.BO's ROE of +0.12%. Regarding short-term risk, PHARMAID.BO is more volatile compared to SHELTER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check SHELTER.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, ROOPAIND.BO has a market cap of 308.2M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while ROOPAIND.BO trades at ₹42.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas ROOPAIND.BO's P/E ratio is 15.93. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to ROOPAIND.BO's ROE of +0.11%. Regarding short-term risk, PHARMAID.BO is less volatile compared to ROOPAIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check ROOPAIND.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SANDUPHQ.BO has a market cap of 294.9M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SANDUPHQ.BO trades at ₹33.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SANDUPHQ.BO's P/E ratio is 14.46. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SANDUPHQ.BO's ROE of +0.05%. Regarding short-term risk, PHARMAID.BO is more volatile compared to SANDUPHQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check SANDUPHQ.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, MEDIORG.NS has a market cap of 294.5M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while MEDIORG.NS trades at ₹22.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas MEDIORG.NS's P/E ratio is 5.77. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to MEDIORG.NS's ROE of N/A. Regarding short-term risk, PHARMAID.BO is more volatile compared to MEDIORG.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check MEDIORG.NS's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, MEDICAPQ.BO has a market cap of 289.3M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while MEDICAPQ.BO trades at ₹23.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas MEDICAPQ.BO's P/E ratio is -6.63. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to MEDICAPQ.BO's ROE of -0.04%. Regarding short-term risk, PHARMAID.BO is less volatile compared to MEDICAPQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check MEDICAPQ.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while TRIMURTHI.BO trades at ₹26.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to TRIMURTHI.BO's ROE of +0.04%. Regarding short-term risk, PHARMAID.BO is more volatile compared to TRIMURTHI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check TRIMURTHI.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, GUJTERC.BO has a market cap of 240.8M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while GUJTERC.BO trades at ₹32.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas GUJTERC.BO's P/E ratio is -16.52. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to GUJTERC.BO's ROE of -0.16%. Regarding short-term risk, PHARMAID.BO is more volatile compared to GUJTERC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check GUJTERC.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, ANG.BO has a market cap of 240.5M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while ANG.BO trades at ₹20.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas ANG.BO's P/E ratio is -2.04. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to ANG.BO's ROE of -0.18%. Regarding short-term risk, PHARMAID.BO is less volatile compared to ANG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check ANG.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, CRSTCHM.BO has a market cap of 233.3M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while CRSTCHM.BO trades at ₹84.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas CRSTCHM.BO's P/E ratio is 10.48. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to CRSTCHM.BO's ROE of +0.30%. Regarding short-term risk, PHARMAID.BO is more volatile compared to CRSTCHM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check CRSTCHM.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, ISHITADR.BO has a market cap of 206.7M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while ISHITADR.BO trades at ₹70.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas ISHITADR.BO's P/E ratio is 23.27. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to ISHITADR.BO's ROE of +0.08%. Regarding short-term risk, PHARMAID.BO is more volatile compared to ISHITADR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check ISHITADR.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while CHEMOPH.BO trades at ₹130.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to CHEMOPH.BO's ROE of -0.93%. Regarding short-term risk, PHARMAID.BO is less volatile compared to CHEMOPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check CHEMOPH.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, DECCAN.BO has a market cap of 169.5M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while DECCAN.BO trades at ₹7.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas DECCAN.BO's P/E ratio is 7.45. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, PHARMAID.BO is more volatile compared to DECCAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check DECCAN.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SUNREST.NS has a market cap of 158.8M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SUNREST.NS trades at ₹37.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SUNREST.NS's P/E ratio is 7.92. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SUNREST.NS's ROE of N/A. Regarding short-term risk, PHARMAID.BO is more volatile compared to SUNREST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check SUNREST.NS's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, ASRL.BO has a market cap of 158M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while ASRL.BO trades at ₹6.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas ASRL.BO's P/E ratio is 14.68. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to ASRL.BO's ROE of +0.01%. Regarding short-term risk, PHARMAID.BO is less volatile compared to ASRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check ASRL.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, NORRIS.BO has a market cap of 133.5M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while NORRIS.BO trades at ₹13.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to NORRIS.BO's ROE of +0.08%. Regarding short-term risk, PHARMAID.BO is less volatile compared to NORRIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check NORRIS.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, ZENITHHE.BO has a market cap of 130M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while ZENITHHE.BO trades at ₹2.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas ZENITHHE.BO's P/E ratio is 30.25. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to ZENITHHE.BO's ROE of +0.06%. Regarding short-term risk, PHARMAID.BO is less volatile compared to ZENITHHE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check ZENITHHE.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, CHCL.BO has a market cap of 125.2M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while CHCL.BO trades at ₹5.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas CHCL.BO's P/E ratio is -0.06. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to CHCL.BO's ROE of -0.21%. Regarding short-term risk, PHARMAID.BO is more volatile compared to CHCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check CHCL.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, DESHRAK.BO has a market cap of 119.7M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while DESHRAK.BO trades at ₹27.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas DESHRAK.BO's P/E ratio is 36.99. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to DESHRAK.BO's ROE of +0.04%. Regarding short-term risk, PHARMAID.BO is more volatile compared to DESHRAK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check DESHRAK.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, EMMESSA.BO has a market cap of 117.7M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while EMMESSA.BO trades at ₹25.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas EMMESSA.BO's P/E ratio is 36.81. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to EMMESSA.BO's ROE of +0.04%. Regarding short-term risk, PHARMAID.BO is less volatile compared to EMMESSA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check EMMESSA.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, SHAMROIN.BO has a market cap of 116.1M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while SHAMROIN.BO trades at ₹21.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas SHAMROIN.BO's P/E ratio is -11.56. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to SHAMROIN.BO's ROE of -0.73%. Regarding short-term risk, PHARMAID.BO is more volatile compared to SHAMROIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check SHAMROIN.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, ZENLABS.BO has a market cap of 113.1M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while ZENLABS.BO trades at ₹18.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas ZENLABS.BO's P/E ratio is -6.12. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to ZENLABS.BO's ROE of -0.18%. Regarding short-term risk, PHARMAID.BO is more volatile compared to ZENLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check ZENLABS.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, COLINZ.BO has a market cap of 112.1M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while COLINZ.BO trades at ₹46.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas COLINZ.BO's P/E ratio is 22.70. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to COLINZ.BO's ROE of +0.05%. Regarding short-term risk, PHARMAID.BO is more volatile compared to COLINZ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check COLINZ.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, PARMAX.BO has a market cap of 106.4M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while PARMAX.BO trades at ₹31.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas PARMAX.BO's P/E ratio is -2.10. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to PARMAX.BO's ROE of +1.49%. Regarding short-term risk, PHARMAID.BO is less volatile compared to PARMAX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PHARMAID.BO.Check PARMAX.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, BERLDRG.BO has a market cap of 97.8M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while BERLDRG.BO trades at ₹18.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas BERLDRG.BO's P/E ratio is 642.67. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to BERLDRG.BO's ROE of +0.00%. Regarding short-term risk, PHARMAID.BO is more volatile compared to BERLDRG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check BERLDRG.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, TRINITYLEA.BO has a market cap of 96.3M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while TRINITYLEA.BO trades at ₹12.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas TRINITYLEA.BO's P/E ratio is -405.67. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to TRINITYLEA.BO's ROE of -0.01%. Regarding short-term risk, PHARMAID.BO is more volatile compared to TRINITYLEA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check TRINITYLEA.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, HINDBIO.BO has a market cap of 79.6M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while HINDBIO.BO trades at ₹7.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas HINDBIO.BO's P/E ratio is 51.80. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to HINDBIO.BO's ROE of +0.17%. Regarding short-term risk, PHARMAID.BO is more volatile compared to HINDBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check HINDBIO.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, ADLINE.BO has a market cap of 73.1M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while ADLINE.BO trades at ₹12.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, PHARMAID.BO is more volatile compared to ADLINE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check ADLINE.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, GANGAPHARM.BO has a market cap of 70.9M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while GANGAPHARM.BO trades at ₹12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas GANGAPHARM.BO's P/E ratio is 109.09. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, PHARMAID.BO is more volatile compared to GANGAPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check GANGAPHARM.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, VIVANZA.BO has a market cap of 70.4M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while VIVANZA.BO trades at ₹1.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas VIVANZA.BO's P/E ratio is -44.00. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to VIVANZA.BO's ROE of -0.03%. Regarding short-term risk, PHARMAID.BO is more volatile compared to VIVANZA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check VIVANZA.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, TIAANC.BO has a market cap of 67.8M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while TIAANC.BO trades at ₹6.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas TIAANC.BO's P/E ratio is -66.00. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, PHARMAID.BO is more volatile compared to TIAANC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check TIAANC.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, EVOQ.BO has a market cap of 57.3M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while EVOQ.BO trades at ₹2.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas EVOQ.BO's P/E ratio is 3.24. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to EVOQ.BO's ROE of +0.04%. Regarding short-term risk, PHARMAID.BO is more volatile compared to EVOQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check EVOQ.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, KOBO.BO has a market cap of 53.1M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while KOBO.BO trades at ₹2.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas KOBO.BO's P/E ratio is -1.05. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, PHARMAID.BO is more volatile compared to KOBO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check KOBO.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, DECIPHER.BO has a market cap of 50.5M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while DECIPHER.BO trades at ₹5.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas DECIPHER.BO's P/E ratio is -0.63. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to DECIPHER.BO's ROE of -0.37%. Regarding short-term risk, PHARMAID.BO is more volatile compared to DECIPHER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check DECIPHER.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, PATIDAR.BO has a market cap of 46.7M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while PATIDAR.BO trades at ₹8.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas PATIDAR.BO's P/E ratio is -17.69. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to PATIDAR.BO's ROE of -0.04%. Regarding short-term risk, PHARMAID.BO is more volatile compared to PATIDAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check PATIDAR.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, TMTIND-B1.BO has a market cap of 36.2M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while TMTIND-B1.BO trades at ₹7.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas TMTIND-B1.BO's P/E ratio is 18.74. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, PHARMAID.BO is more volatile compared to TMTIND-B1.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check TMTIND-B1.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, FABINO.BO has a market cap of 31.9M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while FABINO.BO trades at ₹15.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas FABINO.BO's P/E ratio is -20.81. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, PHARMAID.BO is more volatile compared to FABINO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check FABINO.BO's competition here

PHARMAID.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHARMAID.BO stands at 975.9M. In comparison, WELCURE.BO has a market cap of 27M. Regarding current trading prices, PHARMAID.BO is priced at ₹28.60, while WELCURE.BO trades at ₹0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHARMAID.BO currently has a P/E ratio of -5.40, whereas WELCURE.BO's P/E ratio is 1.04. In terms of profitability, PHARMAID.BO's ROE is -0.24%, compared to WELCURE.BO's ROE of +0.32%. Regarding short-term risk, PHARMAID.BO is more volatile compared to WELCURE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PHARMAID.BO.Check WELCURE.BO's competition here